| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8508822 | Annales Pharmaceutiques Françaises | 2018 | 7 Pages |
Abstract
On logistic, clinical and financial aspects, SU ancillaries need more evaluation. The switch to SU ancillaries allows saving sterilization costs and time, and provided an immediate mobilization of the equipment but their interest must be demonstrated by clinical and economic data.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
J. Steelandt, T. Vaillant, C. Duhamel, S. Haghighat, J.-M. Féron, P. Paubel, A.-L. Cordonnier,